HTFL Heartflowdata gap · 70% coveragelimited data
Health Care · Surgical & Medical Instruments & Apparatus · close $55.43 (2026-10-22) · latest quarter in EDGAR: 2026-06-30
Heartflow (HTFL) has a ThetaGrade House Rating of 57/100 (grade C), ranking #52 of 152 in Health Care. Its strongest pillars are growth (87) and balance sheet (51); its weakest is cash flow (14). Data gap: 4 factors without usable data, so 70% of the method weight is covered. TTM revenue growth is 42.8% and operating margin -37.8%.
Data as of .
Data gap
No usable data for: Consensus score (1–5), 90-day net rating shift, EPS growth YoY (TTM), Net debt / EBITDA. Data gap: no usable data for this factor, so it is left out and its weight is shared among the factors that do have data (no value is imputed). 70% of the full method weight is backed by data.
Analyst sentiment
weight 7.5% · no data · —| Consensus score (1–5) (0.0%)data gap | derived | — |
| 90-day net rating shift (0.0%)data gap | derived | — |
Growth
weight 30.83% (→33.3%) · 87| Revenue growth YoY (TTM) (22.2%) | 42.8% | 88 |
| EPS growth YoY (TTM) (0.0%)data gap | — | — |
| Revenue acceleration (11.1%) | 6.2% | 84 |
Profitability
weight 18.5% (→20.0%) · 50| Operating margin (10.7%) | -37.8% | 11 |
| 4Q gross-margin change (9.3%) | 4.7% | 94 |
Balance sheet
weight 18.5% (→20.0%) · 51| Net debt / EBITDA (0.0%)data gap | — | — |
| Current ratio (11.4%) | 5.08 | 79 |
| Interest coverage (8.6%) | -5.29× | 14 |
Cash flow
weight 12.33% (→13.3%) · 14| FCF margin (6.7%) | -33.5% | 9 |
| FCF yield (6.7%) | -1.2% | 19 |
Valuation
weight 12.33% (→13.3%) · 48| P/E (inverted) (6.7%) | 18.23× | 87 |
| EV/Sales (inverted) (6.7%) | 22.57× | 8 |
Technicals (EOD)
| RSI(14) | 64.3 |
| EMA 9 / 21 | 52.69 / 50.95 |
| 200-day SMA | 33.36 |
| Volume vs 20d avg | 0.79× |
| 20-day return | 17.0% |
Exit-rule monitor
- EXITRating break: House Rating below 60
- EXITBalance-sheet stress: negative free cash flow (latest FY)
Data source per metric (SEC XBRL tag or derivation): Revenue: RevenueFromContractWithCustomerExcludingAssessedTax · Gross profit: GrossProfit · Operating income: OperatingIncomeLoss · Interest expense: InterestExpenseNonoperating · D&A: DepreciationDepletionAndAmortization · EPS: EarningsPerShareDiluted · Market cap: SEC shares (dei EntityCommonStockSharesOutstanding (cover page)) × EOD close · P/E: EOD close ÷ SEC TTM EPS (EarningsPerShareDiluted).
Get rating changes like HTFL's in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium (waitlist).
FAQ
- What is HTFL's House Rating?
- HTFL scores 57 out of 100 (grade C) as of 2026-10-22, ranking #52 of 152 Health Care stocks we cover.
- What do analysts say about HTFL?
- We do not have enough analyst-sentiment data to score this stock.
- When does HTFL report earnings next?
- We do not have a reliable estimate for HTFL's next earnings date (irregular SEC filing history); a rough window is 2026-11-04 to 2026-11-18. Check the company's investor-relations page.
- Is HTFL a buy?
- ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.
Sources: SEC EDGAR filings (fetched 2026-10-23), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology